Australia markets closed
  • ALL ORDS

    7,695.80
    -44.70 (-0.58%)
     
  • AUD/USD

    0.6979
    +0.0051 (+0.74%)
     
  • ASX 200

    7,490.30
    -39.80 (-0.53%)
     
  • OIL

    78.71
    +0.24 (+0.31%)
     
  • GOLD

    1,896.70
    +6.00 (+0.32%)
     
  • BTC-AUD

    32,551.33
    -864.92 (-2.59%)
     
  • CMC Crypto 200

    523.12
    -13.78 (-2.57%)
     

Why Shares of uniQure Rose 14.61% on Wednesday

Why Shares of uniQure Rose 14.61% on Wednesday

Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.